Physician profile
Kishore R Iyer
NPI 1447245303
$94,867.59
in general payments reported to CMS, 2019-2025
9 companies · $27K in 2025
The $27K reported for 2025 was more than what 96% of Transplant Surgery providers received nationally (typical 2025 total: $423).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,228 · 2020: $3,018 · 2021: $7,178 · 2022: $23K · 2023: $9,033 · 2024: $25K · 2025: $27K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $56K · Travel and Lodging: $4,351 · Food and Beverage: $478.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $56,020.45 |
| Travel and Lodging | $4,350.71 |
| Food and Beverage | $478.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $75,604.87 | 2020-2025 | Gattex |
| Vectivbio Ag | $14,279.68 | 2024-2025 | |
| Ipsen Bioscience INC. | $3,540.00 | 2022 | |
| Baxter Healthcare | $1,228.08 | 2019 | |
| Kci USA, INC. | $117.63 | 2020 | |
| Ironwood Pharmaceuticals, INC | $80.00 | 2024 | |
| Fresenius Kabi USA, LLC | $17.33 | 2022 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kishore Iyer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.